Article

Researchers testing a compound treatment for AMD

Gainsville, FL-Scientists at the University of Florida (UF) and researchers in New Hampshire, Minnesota, and Arizona are conducting a new research study, testing an anti-inflammatory compound that has been injected into the eyes of patients with age-related macular degeneration (AMD).

Gainsville, FL-Scientists at the University of Florida (UF) and researchers in New Hampshire, Minnesota, and Arizona are conducting a new research study, testing an anti-inflammatory compound that has been injected into the eyes of patients with age-related macular degeneration (AMD).

The scientists are testing the safety and effectiveness of a synthetic peptide.

The complement inhibitors (Compstatin) developed by Potentia Pharmaceuticals, which is funding the safety trial at UF, have been shown to prevent the inflammatory response that accompanies both wet and dry AMD in animal studies.

POT-4, a derivative of the peptide, has been shown to be a much more active version of the original compound.

"There are now multiple reports that these complement proteins may be over stimulated in wet [AMD]," Kaushal said.

The first three patients of the study have been given the injections and a committee will evaluate the safety of the peptide in the eye. If it is successful another 12 will be tested.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.